Value of serum carbohydrate antigens 19-9 and 24-2 in diagnosis of benign and malignant biliary tract diseases
-
摘要: 目的探讨并分析血清糖链抗原(CA)19-9、CA24-2在良恶性胆道疾病中的诊断价值。方法选取2012年1月-2015年10月于河北北方学院附属第一医院消化内科和普外科住院的胆道疾病患者214例,根据病变性质分为胆道良性病变组(n=162)和恶性病变(胆管癌)组(n=52),另选取同期体检中心健康体检者作为正常对照组(n=40)。所有研究对象均在空腹状态下抽取外周静脉血,检测血清TBil、DBil、IBil,采用放射免疫法测定血清CA19-9、CA24-2水平。计量资料多组样本间比较采用Kruskal-Wallis H检验,进一步两两比较采用Wilcoxon秩和检验;计数资料组间比较采用χ2检验;采用Pearson相关分析法进行相关性分析。结果与正常对照组相比,良、恶性胆道病变组患者血清TBil、CA19-9水平均升高,差异均有统计学意义(P值均<0.01);与胆道良性病变组相比,胆道恶性病变患者血清CA19-9和CA24-2水平均显著升高,差异均有统计学意义(P值均<0.01)。血清CA19-9、CA24-2水平与胆管癌组织学肿瘤位置无关,与组织学不...
-
关键词:
- 胆道疾病 /
- 抗原,肿瘤相关,碳水化合物 /
- 诊断
Abstract: Objective To investigate the value of serum carbohydrate antigen 19- 9( CA19- 9) and carbohydrate antigen 24- 2( CA24-2) in the diagnosis of benign and malignant biliary tract diseases. Methods A total of 214 patients with biliary tract diseases who were hospitalized in Department of Gastroenterology and Department of General Surgery in the First Hospital Affiliated to Hebei North University from January 2012 to October 2015 were enrolled,and according to the nature of lesions,they were divided into benign lesion group( 162 patients) and malignant lesion group( 52 patients). The healthy people who underwent physical examination during the same period of time in the Physical Examination Center were enrolled as normal control group( 40 persons). Peripheral venous blood was collected for all subjects in a fasting state,and the serum levels of total bilirubin( TBil),direct bilirubin( DBil),and indirect bilirubin( IBil) were measured. Radioimmunoassay was used to measure the serum levels of CA19- 9 and CA24- 2. The Kruskal- Wallis H test was used for comparison of continuous data between multiple groups,and the Wilcoxon rank sum test was used for further comparison between any two groups; the chi-square test was used for comparison of categorical data between groups; Pearson correlation analysis was also performed. Results Compared with the normal control group,the benign lesion group and the malignant lesion group showed significant increases in the serum levels of TBil and CA19- 9( all P < 0. 01). Compared with the benign lesion group,the malignant lesion group showed significant increases in the serum levels of CA19- 9 and CA24- 2( all P < 0. 01). The serum levels of CA19- 9 and CA24- 2 were not associated with tumor location in cholangiocarcinoma,but they were associated with the degree of tumor differentiation( χ2= 6. 860 and 9. 010,all P < 0. 05). The combined measurementof CA 1 9- 9 and CA 2 4- 2 had a sensitivity of 8 8. 5 % and a specificity of 8 2. 1 % in the diagnosis of cholangiocarcinoma,which were significantly higher than the sensitivity and specificity of CA19- 9 or CA24- 2 measurement( all P < 0. 01). In the patients with benign biliary tract diseases and cholangiocarcinoma,serum CA19- 9 was positively correlated with serum TBil( r = 0. 634 and 0. 346,both P < 0. 05),and the benign lesion group had a significantly greater correlation between serum CA19- 9 and serum TBil than the malignant lesion group. Conclusion Combined measurement of CA19- 9 and CA24- 2 has clinical significance in early diagnosis of cholangiocarcinoma.-
Key words:
- biliary tract diseases /
- antigens /
- tumor-associated
-
[1]XIONG HL,FAN Y,HU M,et al.The clinical value of serum CA199 in benign and malign biliary tract disease[J].Chin J Clin Gastroenterol,2013,25(6):327-329.(in Chinese)熊会玲,范彦,胡美,等.血清CA199对良恶性胆道疾病的意义[J].临床消化病杂志,2013,25(6):327-329. [2]LIU SL,XING GZ,ZHANG YH,et al.The valuable tumormarkers of CEA and CA19-9 in the bile for diagnosis of cholangiocarcinoma and carcinoma of ampulla[J].J Clin Hepatol,2009,25(2):125-126.(in Chinese)刘素丽,邢国璋,张月寒,等.胆汁CEA、CA19-9联合检测对肝外胆管癌及壶腹癌的诊断价值[J].临床肝胆病杂志,2009,25(2):125-126. [3]JIN ZD,LI ZS.Digestive Ultrasonic Endoscopy[M].Beijing:Science Press,2006:421-548.(in Chinese)金震东,李兆申.消化超声内镜学[M].北京:科学出版社,2006:421-548. [4]CHEN WW,ZHOU SS,YAN S.Value of combined measurement of serum CA19-9 and CA242 in diagnosis of cholangiocarcinoma[J].Zhejiang Clin Med J,2014,16(3):368-369.(in Chinese)陈微微,周思思,严苏.血清CA19-9 CA242联合检测诊断胆管癌的价值[J].浙江临床医学,2014,16(3):368-369. [5]CHUNG YJ,CHOI DW,CHOI SH,et al.Prognostic factors following surgical resection of distal bile duct cancer[J].J Korean Surg Soc,2013,85(5):212-218. [6]DONG CG,WANG SM,SU WB.Research progress on combined measurement of tumor markers in the diagnosis of hilar cholangiocarcinoma[J].China Modern Med,2015,5(22):17-19.(in Chinese)董晨光,王世明,苏文博.肿瘤标志物联合检测在肝门胆管癌诊断中的研究进展[J].中国当代医药,2015,5(22):17-19. [7]ZHU YB,GE SH,ZHANG LH,et al.Clinical value of serum CEA,CA19-9,CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer[J].Chin J Gastrointestinal Surg,2012,15(2):161-164.(in Chinese)朱昱冰,葛少华,张连海,等.肿瘤标志物在胃癌患者中的诊断及预后价值[J].中华胃肠外科杂志,2012,15(2):161-164. [8]CHEN LB,HUANG DB.Diagnostic value of joint determination of serum CA199,CysC and Hcy levels in patients with pancreatic cancer[J].Chin J Health Lab Tec,2014,24(9):1265-1266.(in Chinese)陈乐宝,黄东标.CA199、CysC和Hcy联检对胰腺癌的诊断价值[J].中国卫生检验杂志,2014,24(9):1265-1266. [9]LI J,LIANG XF,ZHAI GL.Application of combined detection of serum levels of CA199,CA125 and CEA in diagnosis of pancreatic cancer[J].J Jilin Univ:Med Edit,2014,40(6):1252-1255.(in Chinese)李静,梁晓芳,翟桂兰.血清CA199、CA125和CEA联合检测在胰腺癌诊断中的应用[J].吉林大学学报:医学版,2014,40(6):1252-1255. [10]HOU JJ,HU SY,LIU TT,et al.Clinical value of serum tumor marker in early diagnosis ovarian cancer[J].Chin J Immunol,2014,30(8):1101-1107.(in Chinese)侯娟娟,虎淑妍,刘婷婷,等.血清肿瘤标志物在卵巢癌早期诊断中的临床价值[J].中国免疫学杂志,2014,30(8):1101-1107. [11]FENG J,SHEN Q,PAN QC.The clinical significance of serum tumor markers in patients with choledocholithiasis[J].Chin J Gastroenterol Hepatol,2016,25(2):212-214.(in Chinese)冯洁,沈强,潘勤聪.胆总管结石患者血清肿瘤标志物的临床意义[J].胃肠病学和肝病学杂志,2016,25(2):212-214. [12]SONG HW,JIANG YG,ZHANG SJ,et al.Relationship of serum CA199 levels with cholangiolithiasis and cholangitis[J].Chin JGastroenterol Hepatol,2013,22(12):1267-1268.(in Chinese)宋惠雯,蒋义贵,张生君,等.血清CA199与胆管结石及胆管炎的关系[J].胃肠病学和肝病学杂志,2013,22(12):1267-1268. [13]TZENG CW,BALACHANDRAN A,AHMAD M,et al.Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer[J].HPB(Oxford),2014,16(5):430-438. [14]CHEN S,MU D,CUI M,et al.Dynamic changes and clinical significance of serum tryptase levels in STEMI patients treated with primary PCI[J].Biomarkers,2014,19(7):620-624. [15]LIN MS,HUANG JX,YU H.Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker[J].Int J Clin Exp Med,2014,7(3):744-750.
本文二维码
计量
- 文章访问数: 2268
- HTML全文浏览量: 6
- PDF下载量: 427
- 被引次数: 0